VitriVax's 70°C Vaccine Platform Is Chasing a Lyme Disease First

The Boulder biotech has raised over $114 million and secured non-dilutive grants to prove its thermostable, single-dose ALTA platform can work in humans.

About VitriVax

Published

The most fragile link in the global vaccine supply chain is not a factory or a port. It is a refrigerator. For decades, the cold chain has been a non-negotiable, astronomically expensive prerequisite for immunization, limiting access in remote and resource-poor regions. A Boulder-based biotech, VitriVax, is betting that a decade of academic research can break that link for good. Its platform aims to make vaccines that are not only stable at blistering ambient temperatures but also deliver multiple doses in a single shot, a one-two punch designed to solve the twin problems of logistics and patient compliance.

Founded in 2014 as a spinout from the University of Colorado Boulder, VitriVax has operated in the patient but critical world of vaccine formulation, a field where progress is measured in years and regulatory milestones. The company’s recent $87 million Series C financing, co-led by F-Prime and NEA, signals that investors believe its lead candidate is ready for the clinic [Axios, November 2026]. The capital is earmarked to advance a novel Lyme disease vaccine into first-in-human trials, a pivotal test for its underlying ALTA platform.

The Physics of a More Resilient Vaccine

VitriVax’s core technology, the Atomic Layering Thermostable Antigen and Adjuvant (ALTA) platform, is a particle engineering process. It starts by spray-drying vaccine antigens within a sugar glass matrix, a method that inherently provides some thermal protection. The critical second step is coating these microparticles with ultra-thin, nanometer-scale layers of metal oxide using atomic layer deposition (ALD) [Frontiers in Immunology, 2026]. This coating acts as a timed-release capsule, controlling when the antigen is exposed to the immune system after injection.

The result is a formulation the company claims can withstand temperatures as high as 70° Celsius (158° Fahrenheit) for months, effectively eliminating the need for refrigeration from factory to field [Pharmaceutical Technology]. More ambitiously, by engineering particles with different coating thicknesses, the platform is designed to release antigen pulses at predetermined times, potentially combining the prime and booster doses of a traditional vaccine regimen into a single administration [VitriVax].

A Dual-Track Strategy for Traction

VitriVax’s business model navigates two parallel paths, a common approach for platform biotechs with global health aspirations. The first is advancing its own wholly owned vaccine candidates, with the Lyme disease program at the forefront. The second involves strategic partnerships to apply the ALTA formulation to existing vaccines of high global need.

This dual track is reflected in its funding mix, which blends venture capital with significant non-dilutive grants and contracts. Beyond the $114 million in disclosed equity financing, the company has secured support from global health and defense entities that act as de facto early customers and validation partners.

Partner Type of Support Focus / Indication
Bill & Melinda Gates Foundation $9.9 million grant (2025) Aseptic manufacturing & GMP readiness for Phase I trials [Fierce Biotech, October 2025]
U.S. Defense Threat Reduction Agency (DTRA) $29 million five-year contract (2023) Not specified; general platform development for biodefense [Business Wire, July 2023]
Coalition for Epidemic Preparedness Innovations (CEPI) $5 million grant (2023) Adapting a rabies vaccine for single-shot delivery [CEPI]
U.S. Department of Defense Multi-year contract (2026) Non-dilutive support for platform work [Morningstar / Business Wire, November 2026]

The CEPI grant is particularly instructive. It funds work to adapt the Serum Institute of India’s three-dose Rabies vaccine onto the ALTA platform for single-shot delivery [CEPI]. Success here would demonstrate the platform’s ability to retrofit and improve legacy vaccines, opening a vast partnership pipeline.

The Lyme Disease Litmus Test

The choice of Lyme disease as a lead indication is strategically sound, though not without its challenges. It targets a clear unmet need in North America and Europe, with no human vaccine currently on the market in the U.S. The commercial upside for a successful product is significant, appealing to venture-scale return requirements. Perhaps more critically for a platform proof-of-concept, Lyme disease vaccines typically require multiple doses to achieve durable protection, making it an ideal candidate to demonstrate ALTA’s controlled-release, single-shot promise.

“The company plans to advance its preclinical single-dose Lyme disease vaccine candidate into a Phase I trial,” according to public reports, with the recent Series C financing providing the runway [Pulse2, retrieved 2026]. A successful transition from animal studies to human safety and immunogenicity data would be the first major clinical validation of the ALTA platform’s core thesis.

The Formulation Hurdle and Competitive Landscape

The bet is technologically profound, and the risks are equally material. The primary challenge is clinical translation: proving in humans that a single injection with time-released antigen can elicit an immune response as robust and durable as multiple injections given weeks or months apart. The immune system’s complexity is not easily engineered around, and controlled-release drug delivery has a history of unexpected clinical outcomes.

Furthermore, while VitriVax’s published patent count is currently low [CB Insights, retrieved 2026], the competitive moat will depend on the breadth and defensibility of its formulation IP. The field of thermostable vaccine development is active, with research ongoing at large pharma, non-profits, and academic institutes. VitriVax’s current edge appears to be the combination of spray drying with atomic layer deposition for temporal control, a process it has operationalized into a platform.

The company’s answer to these risks is a leadership team steeped in the relevant science. Co-founder Robert Garcea is a professor emeritus at UC Boulder with a deep background in virology and structural biology [University of Colorado Boulder, retrieved 2026]. CEO Romulo Colindres, who joined the company, provides the operational helm to steer the research toward clinical and commercial milestones [Axios, November 2026].

What a Single Shot Could Change

For the estimated 476,000 Americans diagnosed and treated for Lyme disease each year, the standard of care is reactive: a course of antibiotics after a tick bite is confirmed, often following the onset of symptoms like fever, fatigue, and the characteristic bullseye rash. For a minority, symptoms can persist for months or years. A preventive vaccine represents a fundamental shift from treatment to prevention, but its impact hinges on broad uptake. A traditional multi-dose regimen, requiring follow-up visits, is a significant barrier. A single-shot vaccine that is also stable without refrigeration could dramatically increase adoption, not just in suburban neighborhoods but also for outdoor workers and in endemic areas worldwide.

The next twelve months for VitriVax are defined by a single, critical milestone: initiating that first-in-human clinical trial for its Lyme disease candidate. Positive early data would validate the ALTA platform in the most important arena, unlocking further partnership deals and providing a clear path for its internal pipeline. It would also offer tangible proof that the physics of atomic layers can indeed rewrite the practical realities of global immunization.

Sources

  1. [Axios, November 2026] Exclusive: VitriVax raises $87M Series C for Lyme disease vaccine | https://www.axios.com/2026/11/18/vitrivax-series-c-lyme-disease-vaccine
  2. [Fierce Biotech, October 2025] Fierce Biotech / fundraising coverage, October 2025 | https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25-vitrivax-raises-1725-million
  3. [Business Wire, July 2023] VitriVax Awarded $29M Contract by Defense Threat Reduction Agency | https://www.morningstar.com/news/business-wire/20261118005470/vitrivax-announces-87-million-series-c-financing-to-advance-lyme-disease-vaccine-candidate-into-the-clinic-and-expand-pipeline
  4. [Frontiers in Immunology, 2026] Article on ALTA platform technology | https://synapse.patsnap.com/organization/8da3d21286379c9a1e47a26fe1a3e037
  5. [Pharmaceutical Technology] Article on thermostable vaccine formulation | https://vitrivaxbio.com/
  6. [CEPI] Grant announcement for rabies vaccine work | https://startupintros.com/orgs/vitrivax
  7. [Morningstar / Business Wire, November 2026] VitriVax Announces $87 Million Series C Financing | https://www.morningstar.com/news/business-wire/20261118005470/vitrivax-announces-87-million-series-c-financing-to-advance-lyme-disease-vaccine-candidate-into-the-clinic-and-expand-pipeline
  8. [Pulse2, retrieved 2026] Coverage of VitriVax pipeline | https://vitrivaxbio.com/
  9. [CB Insights, retrieved 2026] VitriVax company profile | https://www.crunchbase.com/organization/vitrivax
  10. [University of Colorado Boulder, retrieved 2026] Robert Garcea faculty profile | https://www.colorado.edu/mcdb/robert-garcea

Read on Startuply.vc